{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:19:36Z","timestamp":1787019576932,"version":"build-2736575974"},"reference-count":18,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Quadruplet induction regimens containing anti-CD38 monoclonal antibodies in combination with a triplet backbone are providing deeper and more durable responses in newly diagnosed multiple myeloma (NDMM) patients, and at the same time, questioning the role of autologous stem cell transplant as part of consolidation, especially in certain subgroups. While several studies are evaluating the rate of sustained minimal residual disease (MRD) achieved when combining quadruplet regimens to transplant, other studies are focusing on the relevance of pursuing transplant in those who achieved MRD with induction. Current evidence supports autologous stem cell transplant as a key consolidation strategy while ongoing studies refine risk-adapted and MRD-guided approaches. We have yet to see how new immunotherapies that are moving to front-line therapy will challenge the role of transplant in the future.<\/jats:p>","DOI":"10.1182\/hematology.2025000730","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:08:53Z","timestamp":1764943733000},"page":"401-404","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Transplant in myeloma: what is its role?"],"prefix":"10.1182","volume":"2025","author":[{"given":"Cesar","family":"Rodriguez","sequence":"first","affiliation":[{"name":"Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"10068","key":"2025120616335428700_hem2025000730C1","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in newly diagnosed multiple myeloma without intent for immediate autologous stem-cell transplant","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"14","key":"2025120616335428700_hem2025000730C2","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2025120616335428700_hem2025000730C3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-134538","article-title":"Early vs late ASCT in newly diagnosed MM: long-term follow-up of IFM-2009","volume":"136","author":"Perrot","year":"2020","journal-title":"Blood"},{"issue":"2","key":"2025120616335428700_hem2025000730C4","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"2025120616335428700_hem2025000730C5","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1200\/JCO-24-02266","article-title":"Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 trial","volume":"43","author":"Mai","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2025120616335428700_hem2025000730C6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2023-177546","article-title":"Results of the phase III randomized IsKia trial: isatuximab\u2013carfilzomib\u2013lenalidomide\u2013dexamethasone vs carfilzomib\u2013lenalidomide\u2013dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients","volume":"142","author":"Gay","year":"2023","journal-title":"Blood"},{"issue":"7","key":"2025120616335428700_hem2025000730C7","first-page":"658","article-title":"Minimal residual disease\u2013guided autologous transplantation versus continued quadruplet therapy in newly diagnosed multiple myeloma: results from the MIDAS trial","volume":"392","author":"Perrot","year":"2025","journal-title":"N Engl J Med"},{"issue":"suppl 15","key":"2025120616335428700_hem2025000730C8","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2019.37.15_suppl.8002","article-title":"KRd with or without transplant in NDMM: results from FORTE trial","volume":"37","author":"Gay","year":"2019","journal-title":"J Clin Oncol"},{"issue":"25","key":"2025120616335428700_hem2025000730C9","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response\u2013adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025120616335428700_hem2025000730C10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"suppl 16","key":"2025120616335428700_hem2025000730C11","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1200\/JCO.2025.43.16_suppl.7501","article-title":"Subcutaneous daratumumab (dara) + bortezomib\/lenalidomide\/dexamethasone (VRd) with Dara+ lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): Analysis of sustained minimal residual disease negativity in the phase 3 PERSEUS trial","volume":"43","author":"Moreau","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025120616335428700_hem2025000730C12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma","volume":"42","author":"Leypoldt","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"2025120616335428700_hem2025000730C13","article-title":"Sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib- lenalidomide-dexamethasone with or without isatuximab (phase III IsKia trial)","volume":"43","author":"Gay","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025120616335428700_hem2025000730C14","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible or transplant- deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"2025120616335428700_hem2025000730C15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jgo.2019.05.014","article-title":"Autologous stem cell transplant in older patients (age &gt; 65) with newly diagnosed multiple myeloma: A systematic review and meta-analysis","volume":"11","author":"Mian","year":"2020","journal-title":"J Geriatr Oncol"},{"issue":"8","key":"2025120616335428700_hem2025000730C16","first-page":"E171","article-title":"Transplant eligibility in elderly multiple myeloma patients: prospective external validation of the International Myeloma Working Group frailty score and comparison with clinical judgment and other comobidity scores in unsselected patients aged 65-75 years","volume":"95","author":"Belotti","year":"2020","journal-title":"Am J Hematol"},{"issue":"1","key":"2025120616335428700_hem2025000730C17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3324\/haematol.2020.262360","article-title":"Autologous stem cell transplantation is safe and effective for fit, older myeloma patients: exploratory results from the Myeloma XI trial","volume":"107","author":"Pawlyn","year":"2022","journal-title":"Haematologica"},{"issue":"Suppl 6","key":"2025120616335428700_hem2025000730C18","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.htct.2023.07.012","article-title":"Autologous stem cell transplantation in patients older than 65 years with multiple myeloma: A real-world study","volume":"46","author":"Seehaus","year":"2024","journal-title":"Hematol Transfus Cell Ther"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/401\/2470058\/401rodriguez.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/401\/2470058\/401rodriguez.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:34:01Z","timestamp":1765056841000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2025\/1\/401\/556898\/Transplant-in-myeloma-what-is-its-role"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,5]]},"published-print":{"date-parts":[[2025,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2025000730","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,5]]},"published":{"date-parts":[[2025,12,5]]}}}